Risk-adapted treatment reduced chemotherapy exposure for clinical stage I pediatric testicular cancer.

ABSTRACT:

Background

Different from adult clinical stage I (CS1) testicular cancer, surveillance has been recommended for CS1 pediatric testicular cancer. However, among high-risk children, more than 50% suffer a relapse and progression during surveillance, and adjuvant chemotherapy needs to be administered. Risk-adapted treatment might reduce chemotherapy exposure among these children.

Methods

A decision model was designed and calculated using TreeAge Pro 2011 software. Clinical utilities such as the relapse rates of different groups during surveillance or after chemotherapy were collected from the literature. A survey of urologists was conducted to evaluate the toxicity of first-line and second-line chemotherapy. Using the decision analysis model, chemotherapy exposure of the risk-a

SUBMITTER: Ye YL 

PROVIDER: S-EPMC7737364 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature